KALV - What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? | Benzinga
KalVista Pharmaceuticals Inc (NASDAQ:KALV) released results from the phase 3 KONFIDENT trial demonstrating statistically and clinically significant efficacy of sebetralstat as an oral on-demand therapy for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling (angioedema).
KalVista Pharmaceuticals says KONFIDENT trial was the largest and most representative trial ever conducted in HAE and included adolescents, patients using long-term prophylaxis, and all attack severities and locations.
The trial met all primary and key secondary endpoints and demonstrated a favorable safety profile.
HAE attacks treated with 300 mg and 600 mg ...